A nonprofit division of Sevadar Foundation Inc.

For clinicians  ·  For facilities  ·  For families  ·  For staff

For prescribing clinicians

For prescribing clinicians

You are not the audience that needs convincing that medication lists get long. You are the audience that inherits one, at a fifteen-minute appointment, without the three prescribers who built it. These pages are about the process and the evidence, not about the principle.

What this site takes as settled

  • Deprescribing is safe. Across 118 randomized trials and 417,412 patients aged 65 and over, interventions to address potentially inappropriate prescribing showed no signal of harm on adverse drug reactions, injurious falls, quality of life, medical visits, emergency admissions, hospitalizations or mortality.
  • It reduces medication count and that is mostly what it has been shown to do — about half a medication per patient in that synthesis.
  • The drugs raise fall risk; removing them has not been shown to lower it. Sedating medications impair gait, balance and reaction time and their labels say so, while five independent syntheses found no reduction in fall rates from deprescribing programs. The evidence.
  • The mortality claim did not replicate. The 2024 update of the largest meta-analysis, covering 259 studies, found no significant reduction in randomized studies.
  • Most patients say yes when asked. In the Shed-MEDS trial, participants or surrogates agreed with 63% of clinician deprescribing recommendations across 883 medications. The barrier is more often the conversation not happening than refusal.

The pages

The medication review

Reading a list as one object, in date order, and the questions that make it a review rather than a sign-off.

Tapering principles

Which classes require a taper, what the regulators say about rate, and what makes the difference between a taper and a withdrawal.

Prescribing cascades

A drug causes a symptom; the symptom becomes a diagnosis. Only visible when the list is read in the order it was written.

Tools and references

The criteria sets, the burden scales, the guidelines, and what each is actually validated for.

The drug classes

The drug-class library covers opioids, benzodiazepines, Z-drugs, antipsychotics, anticholinergic burden, proton pump inhibitors, statins in the very old, antihypertensives and gabapentinoids — each with what changes with age, what the evidence supports, and where it is thinner than the confidence around it.

On the framing this site uses

Two things it will not do. It will not present deprescribing as something performed on a patient — the evidence on imposed opioid tapering is sufficient warning about where that leads. And it will not overstate the benefits, because a promise that does not survive contact with a fall rate discredits the parts of this that are solid.

What DWARAA is, and is not

DWARAA does not prescribe, deprescribe, diagnose or treat. Those are decisions made by a patient and their own clinicians, with the whole record in front of them. What DWARAA supplies is the framework, the evidence behind it, and the shared vocabulary that lets a family, a nurse, a facility and a prescriber talk about the same medication list and mean the same thing.

Common questions

Is there a target number of medications?

No, and this site does not publish one. “Five or more” is a research counting convention, not a clinical threshold. Pharmacologic load — anticholinergic and sedative exposure — tracks physical function considerably better than a count does. Polypharmacy in long-term care.

What is the strongest single argument for doing this?

That a substantial share of long-term care prescriptions have no recorded indication at all — most starkly with proton pump inhibitors, where 65.3% of prescriptions in one US skilled-nursing study had no supporting diagnostic code. A drug treating nothing has only risk. Proton pump inhibitors.

Cognitive decline, care burden and the vascular argument

A companion page draws together the material that most often gets overstated in this field: how care intensity actually scales with cognitive severity, why the cost gradient is largely a composition effect, the separation of three different claims about medication and memory, and the antipsychotic stroke evidence with its qualifications. It also sets out the cascade from sedating medication to fall to hip fracture — including that in 60,111 US nursing home residents, 36.2% were dead within 180 days of a hip fracture and 53.5% of those previously mobile had died or become newly totally dependent in locomotion.

Cognitive decline, care burden, and where the medication list sits.

What the evidence does and does not show

Deprescribing on its own has not been shown to reduce falls. That is the honest state of the evidence, and it is worth saying plainly because the opposite is so often assumed. Reducing a medication list reliably reduces the number of potentially inappropriate medications a person is taking. It has not been shown, in the trials that tested it, to produce a measurable drop in falls or fractures. What the evidence actually shows about deprescribing and falls.

References

  1. Persaud N, Workentin A, Rizvi A, et al. Interventions to Address Potentially Inappropriate Prescribing for Older Primary Care Patients: A Systematic Review and Meta-Analysis. JAMA Network Open. 2025;8(6):e2517965. PMID 40577011 · DOI 10.1001/jamanetworkopen.2025.17965.
  2. Quek HW, Page A, Lee K, et al. The effect of deprescribing interventions on mortality and health outcomes in older people: An updated systematic review and meta-analysis. British Journal of Clinical Pharmacology. 2024;90(10):2409–2482. PMID 39164070 · DOI 10.1111/bcp.16200.
  3. Kim JL, Lewallen KM, Hollingsworth EK, Shah AS, Simmons SF, Vasilevskis EE. Patient-Reported Barriers and Enablers to Deprescribing Recommendations During a Clinical Trial (Shed-MEDS). The Gerontologist. 2023;63(3):523–533. PMID 35881109 · DOI 10.1093/geront/gnac100.
  4. Lee J, Negm A, Peters R, Wong EKC, Holbrook A. Deprescribing fall-risk increasing drugs (FRIDs) for the prevention of falls and fall-related complications: a systematic review and meta-analysis. BMJ Open. 2021;11(2):e035978. PMID 33568364 · DOI 10.1136/bmjopen-2019-035978.
  5. Patterson Burdsall D, Flores HC, Krueger J, et al. Use of proton pump inhibitors with lack of diagnostic indications in 22 Midwestern US skilled nursing facilities. Journal of the American Medical Directors Association. 2013;14(6):429–432. PMID 23583000 · DOI 10.1016/j.jamda.2013.01.021.
  6. Neuman MD, Silber JH, Magaziner JS, Passarella MA, Mehta S, Werner RM. Survival and functional outcomes after hip fracture among nursing home residents. JAMA Internal Medicine. 2014;174(8):1273–1280. PMID 25055155 · DOI 10.1001/jamainternmed.2014.2362.

Bibliographic records on this page were retrieved from PubMed. Every reference links to its DOI or PubMed record.

Written and medically reviewed by Dr. Gurpreet Singh Padda, MD, MBA, MHP, founder and medical director of DWARAA. Last reviewed . This page is educational. DWARAA does not prescribe, deprescribe, diagnose or treat.